Shares of Celldex Therapeutics Inc. (NASDAQ:CLDX) were down 4% during mid-day trading on Tuesday . The company traded as low as $4.51 and last traded at $4.52, with a volume of 875,303 shares changing hands. The stock had previously closed at $4.71.

A number of brokerages recently weighed in on CLDX. Roth Capital reissued a “buy” rating and set a $7.00 price objective on shares of Celldex Therapeutics in a report on Tuesday, April 19th. Jefferies Group reissued a “hold” rating and set a $4.00 price objective on shares of Celldex Therapeutics in a report on Friday, May 6th. Wedbush reissued a “neutral” rating and set a $3.00 price objective on shares of Celldex Therapeutics in a report on Friday, May 6th. Finally, Cowen and Company reissued an “outperform” rating and set a $12.00 price objective on shares of Celldex Therapeutics in a report on Tuesday, June 7th. Six investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Celldex Therapeutics currently has a consensus rating of “Hold” and an average target price of $14.11.

The stock’s 50-day moving average is $4.49 and its 200-day moving average is $5.73. The firm’s market cap is $442.26 million.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.35). During the same period last year, the company earned ($0.33) EPS. The business earned $1.30 million during the quarter, compared to the consensus estimate of $1.06 million. The business’s revenue was up 160.0% on a year-over-year basis. Equities analysts anticipate that Celldex Therapeutics Inc. will post ($1.36) EPS for the current fiscal year.

Several institutional investors have added to or reduced their stakes in the company. Columbia Wanger Asset Management LLC raised its position in Celldex Therapeutics by 16.1% in the fourth quarter. Columbia Wanger Asset Management LLC now owns 3,610,008 shares of the biopharmaceutical company’s stock worth $56,605,000 after buying an additional 500,393 shares during the period. ProShare Advisors LLC raised its position in Celldex Therapeutics by 10.7% in the fourth quarter. ProShare Advisors LLC now owns 93,666 shares of the biopharmaceutical company’s stock worth $1,469,000 after buying an additional 9,072 shares during the period. TSP Capital Management Group LLC raised its position in Celldex Therapeutics by 0.8% in the fourth quarter. TSP Capital Management Group LLC now owns 831,648 shares of the biopharmaceutical company’s stock worth $13,040,000 after buying an additional 6,967 shares during the period. Bedell Frazier Investment Counseling LLC raised its position in Celldex Therapeutics by 9.0% in the fourth quarter. Bedell Frazier Investment Counseling LLC now owns 65,236 shares of the biopharmaceutical company’s stock worth $1,023,000 after buying an additional 5,411 shares during the period. Finally, Rhumbline Advisers raised its position in Celldex Therapeutics by 4.9% in the fourth quarter. Rhumbline Advisers now owns 108,426 shares of the biopharmaceutical company’s stock worth $1,700,000 after buying an additional 5,110 shares during the period.

Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.